Point: Active Surveillance for Favorable Risk Prostate Cancer

Active surveillance for favorable risk prostate cancer has become increasingly popular in populations where prostate cancer screening is widespread, because of evidence that prostate cancer screening results in the detection of disease that is not clinically significant in many patients (i.e., untreated, would not pose a threat to health). This approach is supported by data showing that patients who fall into the category of clinically insignificant disease can be identified with reasonable accuracy, and that patients who are initially classified as low-risk who reclassify over time as higher-risk and are treated radically are still cured in most cases. Active surveillance means 1) identifying patients who have a low likelihood of disease progression during their lifetime, based on clinical and pathologic features of the disease, and patient age and comorbidity; 2) close monitoring over time; 3) developing reasonable criteria for intervention, which will identify more aggressive disease in a timely fashion and not result in excessive treatment; and 4) meeting the communication challenge to reduce the psychological burden of living with untreated cancer. This article reviews the results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Dr. Laurence Klotz, MD, FRCSC, University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue #MG408, Toronto, Ontario M4N 3M5. E-mail: Laurence.klotz@sunnybrook.ca

References

  • 1.

    WelchHGSchwartzLMWoloshinS. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst2005;97:11321137.

    • Search Google Scholar
    • Export Citation
  • 2.

    JemalATiwariRCMurrayT. Cancer statistics, 2004. CA Cancer J Clin2004;54:829.

  • 3.

    D'AmicoAVWhittingtonRMalkowiczSB. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998;280:969974.

    • Search Google Scholar
    • Export Citation
  • 4.

    SakrWAHaasGPCassinBF. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol1993;150:379385.

    • Search Google Scholar
    • Export Citation
  • 5.

    AlbertsenPHanleyJAFineJ. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA2005;293:20952101.

    • Search Google Scholar
    • Export Citation
  • 6.

    AlbertsenPCHanleyJABarrowsGH. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst2005;97:12481253.

  • 7.

    StameyTAFreihaFSMcNealJE. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer1993;71:933938.

    • Search Google Scholar
    • Export Citation
  • 8.

    EpsteinJIWalshPCCarmichaelM. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994;271:368374.

    • Search Google Scholar
    • Export Citation
  • 9.

    EpsteinJIPizovGWalshPC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer1993;71:35823593.

    • Search Google Scholar
    • Export Citation
  • 10.

    IrwinMBTrapassoJG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology1994;44:862867; discussion 867–868.

    • Search Google Scholar
    • Export Citation
  • 11.

    CuppMRBostwickDGMyersRPOesterlingJE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol1995;153:15431548.

    • Search Google Scholar
    • Export Citation
  • 12.

    GotoYOhoriMArakawaA. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol1996;156:10591063.

    • Search Google Scholar
    • Export Citation
  • 13.

    EpsteinJICarmichaelMPartinAW. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol1993;149:14781481.

    • Search Google Scholar
    • Export Citation
  • 14.

    EpsteinJIChanDWSokollLJ. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol1998;160:24072411.

    • Search Google Scholar
    • Export Citation
  • 15.

    NoguchiMStameyTAMcNealJEYemotoCM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol2001;166:104109.

    • Search Google Scholar
    • Export Citation
  • 16.

    AugustinHHammererPGGraefenM. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol2003;43:455460.

    • Search Google Scholar
    • Export Citation
  • 17.

    AnastJWAndrioleGLBismarTA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?Urology2004;64:544550.

    • Search Google Scholar
    • Export Citation
  • 18.

    ChooRDeBoerGKlotzL. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys2001;50:615620.

    • Search Google Scholar
    • Export Citation
  • 19.

    KakehiY. PSA DT in Japanese active surveillance cohort (48 patients). Jpn J Clin Oncol2003;33:15.

  • 20.

    EgawaSAraiYTobisuK. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis2000;3:269274.

    • Search Google Scholar
    • Export Citation
  • 21.

    McLarenDBMcKenzieMDuncanG. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer1998;82:342348.

    • Search Google Scholar
    • Export Citation
  • 22.

    D'AmicoAVChenMHRoehlKACatalonaWJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med2004;351:125135.

    • Search Google Scholar
    • Export Citation
  • 23.

    ChooRKlotzLDanjouxC. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol2002;167:16641669.

    • Search Google Scholar
    • Export Citation
  • 24.

    KlotzL. Active surveillance for prostate cancer: for whom?J Clin Oncol2005;23:81658169.

  • 25.

    Bill-AxelsonAHolmbergLRuutuM. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2005;352:19771984.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 23 23 4
PDF Downloads 6 6 2
EPUB Downloads 0 0 0